Compare Recursion Pharmaceuticals Inc (RXRX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Valero Energy Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while Valero Energy Corporation trades at $323.5 (market cap $90.68B). The key difference: Valero Energy Corporation is far larger — about 50.9× Recursion Pharmaceuticals Inc's market cap, and Valero Energy Corporation pays a 1.52% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VLO | |
|---|---|---|
Market Cap | $1.78B | $90.68B |
Sector | Health | Energy |
52-Week High | $6.79 | $323.92 |
52-Week Low | $2.84 | $133.38 |
Enterprise Value | $1.30B | $94.16B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Valero Energy (VLO) trades at $298.31, down 1.54% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 29.31% ROE and trades at a P/E of 12.44, below industry averages. Recent news highlights geopolitical tensions supporting refining margins, while Q2 2026 earnings surged on strong refining and renewable diesel performance.
Outlook remains positive with a consensus price target of $324.27, implying 8.7% upside, but risks include volatile oil prices and declining revenue trends. Analyst sentiment is bullish with 55.55% buy ratings, though technical indicators suggest near-term caution amid bearish momentum signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
